相关产品推荐更多 >

CLEC4D Polyclonal Antibody(多克隆抗体) | CLEC4D Antibody | CLEC4D抗体
¥1100
Anti-Human CD85g/LILRA4 Antibody (SAA0038), APC
¥1740
MED18 Polyclonal Antibody(多克隆抗体), FITC conjugated | MED18 Antibody, FITC conjugated | MED18抗体, FITC conjugated
¥880
UBA6 Polyclonal Antibody(多克隆抗体), Biotin conjugated | UBA6 Antibody, Biotin conjugated | UBA6抗体, Biotin conjugated
¥880
MADCAM1 Polyclonal Antibody(多克隆抗体), Biotin conjugated | MADCAM1 Antibody, Biotin conjugated | MADCAM1抗体, Biotin conjugated
¥880
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 亚型:
IgG1-kappa
- 形态:
Liquid
- 保存条件:
-20°C
- 克隆性:
单克隆
- 适应物种:
Human
- 保质期:
12 months
- 级别:
一抗
- 供应商:
武汉研升生物科技有限公司
- 宿主:
Humanized
- 应用范围:
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- 抗体英文名:
Research Grade Rovalpituzumab
- 规格:
100μg/1mg
| 规格: | 100μg | 产品价格: | ¥598.0 |
|---|---|---|---|
| 规格: | 1mg | 产品价格: | ¥2488.0 |
| 产品名 | Research Grade Rovalpituzumab |
| 货号 | HP628016 |
| 别名 | SC0001-SCX, SC0002, 1613313-01-1 |
| 表达系统 | Mammalian Cells |
| 靶标 | Drosophila Delta homolog 3, Delta3, Delta-like protein 3, DLL3 |
| Accession号 | Q9NYJ7 |
| 宿主 | Humanized |
| 种属反应性 | Human |
| 克隆性 | Monoclonal |
| 同种型 | IgG1-kappa |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 状态 | Liquid |
| 背景 | Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC). • Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer., PMID:37355629 • Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer., PMID:30894499 • DLL3: an emerging target in small cell lung cancer., PMID:31215500 • Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study., PMID:36689692 • AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer., PMID:33203642 • DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms., PMID:35983951 • A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo., PMID:26311731 • IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models., PMID:36951942 • HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors., PMID:38670552 • Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)., PMID:37694295 |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 说明 | For research use only. Not suitable for clinical or therapeutic use. |

风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Characterization and Quality Control of Antibodies Used in ChIP Assays
epigenetics research tools based on everyday’s researcher’s needs by providing batch-specific fully characterized ChIP-grade antibodies.
相关专题 his method was successful in our lab using prostate tissue and for our specific objectives. Investigators must be aware that they will need to tailor the following protocol for their own research objectives
®尤其在皮肤组织的表皮分离和上皮层细胞培养中获得了广泛的应用。Dispase®I与Dispase®II两者的差别在于纯度的不同,Dispase®I经过滤除菌,且每mg Dispase®I的纯度和酶活远高于Dispase®II。 罗氏高纯度研究级别酶混合物Liberase Research Grade Enzyme Blends Liberase Research Grade Enzyme Blends包含了一系列酶混合物,它们由不同比例的中性蛋白酶(非梭菌蛋白酶)和高纯
技术资料暂无技术资料 索取技术资料





